Kang Sung Hoon, Kim Jong Hyuk, Chang Yoosoo, Cheon Bo Kyoung, Choe Yeong Sim, Jang Hyemin, Kim Hee Jin, Koh Seong-Beom, Na Duk L, Kim Kyunga, Seo Sang Won
Department of Neurology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea.
Neuroscience Center, Samsung Medical Center, Seoul, South Korea.
Front Aging Neurosci. 2022 Jul 22;14:924550. doi: 10.3389/fnagi.2022.924550. eCollection 2022.
The relationship of body mass index (BMI) changes and variability with amyloid-β (Aβ) deposition remained unclear, although there were growing evidence that BMI is associated with the risk of developing cognitive impairment or AD dementia. To determine whether BMI changes and BMI variability affected Aβ positivity, we investigated the association of BMI changes and BMI variability with Aβ positivity, as assessed by PET in a non-demented population.
We retrospectively recruited 1,035 non-demented participants ≥50 years of age who underwent Aβ PET and had at least three BMI measurements in the memory clinic at Samsung Medical Center. To investigate the association between BMI change and variability with Aβ deposition, we performed multivariable logistic regression. Further distinctive underlying features of BMI subgroups were examined by employing a cluster analysis model.
Decreased (odds ratio [OR] = 1.68, 95% confidence interval [CI] 1.16-2.42) or increased BMI (OR = 1.60, 95% CI 1.11-2.32) was associated with a greater risk of Aβ positivity after controlling for age, sex, APOE e4 genotype, years of education, hypertension, diabetes, baseline BMI, and BMI variability. A greater BMI variability (OR = 1.73, 95% CI 1.07-2.80) was associated with a greater risk of Aβ positivity after controlling for age, sex, APOE e4 genotype, years of education, hypertension, diabetes, baseline BMI, and BMI change. We also identified BMI subgroups showing a greater risk of Aβ positivity.
Our findings suggest that participants with BMI change, especially those with greater BMI variability, are more vulnerable to Aβ deposition regardless of baseline BMI. Furthermore, our results may contribute to the design of strategies to prevent Aβ deposition with respect to weight control.
尽管越来越多的证据表明体重指数（BMI）与认知障碍或阿尔茨海默病性痴呆的发生风险相关，但BMI变化及变异性与β淀粉样蛋白（Aβ）沉积之间的关系仍不明确。为了确定BMI变化和BMI变异性是否会影响Aβ阳性，我们在一个非痴呆人群中，通过PET评估研究了BMI变化和BMI变异性与Aβ阳性之间的关联。
我们回顾性招募了1035名年龄≥50岁的非痴呆参与者，他们在三星医疗中心记忆门诊接受了Aβ PET检查，并且至少有三次BMI测量值。为了研究BMI变化和变异性与Aβ沉积之间的关联，我们进行了多变量逻辑回归分析。通过采用聚类分析模型，进一步研究了BMI亚组的独特潜在特征。
在控制了年龄、性别、APOE e4基因型、受教育年限、高血压、糖尿病、基线BMI和BMI变异性后，BMI降低（比值比[OR]=1.68，95%置信区间[CI] 1.16 - 2.42）或升高（OR = 1.60，95% CI 1.11 - 2.32）与Aβ阳性风险增加相关。在控制了年龄、性别、APOE e4基因型、受教育年限、高血压、糖尿病、基线BMI和BMI变化后，更大的BMI变异性（OR = 1.73，95% CI 1.07 - 2.80）与Aβ阳性风险增加相关。我们还识别出了显示Aβ阳性风险更高的BMI亚组。
我们的研究结果表明，无论基线BMI如何，BMI发生变化的参与者，尤其是BMI变异性更大的参与者，更容易发生Aβ沉积。此外，我们的结果可能有助于设计针对体重控制预防Aβ沉积的策略。
